 |
|
UNC study questions FDA genetic-screening guidelines for cancer drug
August 29, 2007CHAPEL HILL - Not everyone needs a genetic test before taking the cancer drug irinotecan, and the U.S. Food and Drug Administration should modify its prescription guidelines to say so, according to researchers at the University of North Carolina at Chapel Hill.
Irinotecan, also known by its brand name Camptosar, is used mainly as a second-line treatment for colorectal cancer. The FDA recommends screening patients for a gene that could make them more susceptible to the harmful side effects of the drug, the most worrisome of which is neutropenia, an abnormally low number of white blood cells.
In a paper published in the Aug. 28, 2007 Journal of the National Cancer Institute, UNC researchers analyzed data from nine previous studies of irinotecan. They found that patients who received a medium or high dose of the drug had greater risk of neutropenia if they had two copies of a variation of the gene UGT1A1, known as UGT1A1*28. At lower doses, however, the risk was the same regardless of what UGT1A1 gene the patients had.
"Many institutions saw the FDA's recommendation as a mandate to test all patients before treating them with irinotecan even though many clinicians didn't think it was always necessary given that low doses of the drug weren't causing problems," said Howard McLeod, Pharm.D., senior author of the study and director of the UNC Institute for Pharmacogenomics and Individualized Therapy.
"Our review showed that at low doses the drug is well tolerated and can be taken by most people," McLeod said. "As the dosage increases, genetics become a larger factor in determining what side effects patients experience, and then testing becomes essential."
Having a genetic test available for a medicine is valuable, but so is knowing when to use that test, said Dr. Richard Goldberg, a co-author of the study and physician in chief of the North Carolina Cancer Hospital.
"There are so many treatment options for cancer patients that the more information we have about matching the right therapy to the patient, the better off we all are," Goldberg said. "Studies like this one give oncologists the tools needed to take better care of patients while avoiding tests and expenses that aren't needed."
The authors recommended that the FDA amend the product information for irinotecan to describe the association between irinotecan dose and risk of hematologic toxicity among patients with two UGT1A1*28 genes.
University of North Carolina at Chapel Hill
"Many institutions saw the FDA's recommendation as a mandate to test all patients before treating them with irinotecan even though many clinicians didn't think it was always necessary given that low doses of the drug weren't causing problems," said Howard McLeod, Pharm.D., senior author of the study and director of the UNC Institute for Pharmacogenomics and Individualized Therapy.
"Our review showed that at low doses the drug is well tolerated and can be taken by most people," McLeod said. "As the dosage increases, genetics become a larger factor in determining what side effects patients experience, and then testing becomes essential."
Having a genetic test available for a medicine is valuable, but so is knowing when to use that test, said Dr. Richard Goldberg, a co-author of the study and physician in chief of the North Carolina Cancer Hospital.
"There are so many treatment options for cancer patients that the more information we have about matching the right therapy to the patient, the better off we all are," Goldberg said. "Studies like this one give oncologists the tools needed to take better care of patients while avoiding tests and expenses that aren't needed."
The authors recommended that the FDA amend the product information for irinotecan to describe the association between irinotecan dose and risk of hematologic toxicity among patients with two UGT1A1*28 genes.
University of North Carolina at Chapel Hill
Cancer Drug Current Events and Cancer Drug News RSSStopping germs from ganging up on humans
Keeping germs from cooperating can delay the evolution of drug resistance more effectively than killing germs one by one with traditional drugs such as antibiotics, according to new research from The University of Arizona in Tucson.
Herbal Menopause Therapy a Good Fit for Breast Cancer Patients?
When it comes to understanding the effectiveness and safety of using herbal therapies with other drugs, much is unknown. Now, a University of Missouri researcher will study how black cohosh - an herbal supplement often used to relieve hot flashes in menopausal women - interacts with tamoxifen, a common drug used to treat breast cancer.
Burnham Researchers Turn Cancer Friend into Cancer Foe
Burnham Institute for Medical Research today announced that scientists have created a peptide that binds to Bcl-2, a protein that protects cancer cells from programmed cell death, and converts it into a cancer cell killer.
Anti-cancer drug prevents, reverses cardiovascular damage in mouse model of premature aging disorder
An experimental anti-cancer drug can prevent -- and even reverse -- potentially fatal cardiovascular damage in a mouse model of progeria, a rare genetic disorder that causes the most dramatic form of human premature aging, National Institutes of Health (NIH) researchers reported today.
Rare genetic disorder gives clues to autism, epilepsy, mental retardation
A rare genetic disorder called tuberous sclerosis complex (TSC) is yielding insight into a possible cause of some neurodevelopmental disorders: structural abnormalities in neurons, or brain cells.
The dietary supplement genistein can undermine breast cancer treatment
Women taking aromatase inhibitors to treat breast cancer or prevent its recurrence should think twice before also taking a soy-based dietary supplement, researchers report.
As head and neck cancer risks evolve, more treatment options emerge
Advances in understanding head and neck cancer over the last decade have led to more treatment options and improved quality of life for patients, according to a review published this week in the New England Journal of Medicine.
Research Ethics Committees identify and correct problems in applications to do cancer trials
Researchers running cancer trials are often critical of the Research Ethics Committee (REC) process they have to go through to get their trials approved, complaining that it's too complex, burdensome and sometimes unreasonable. In the UK only 17% of research study applications are given immediate favourable opinion by RECs.
Anti-Cancer Flower Power
Could a substance from the jasmine flower hold the key to an effective new therapy to treat cancer?
Yale undergrads' Amazon trip yields a treasure trove of diversity
A group of Yale undergraduates have discovered dozens of potentially beneficial bioactive microorganisms within plants they collected in the Amazon rain forest, including several so genetically distinct that they may be the first members of new taxonomical genera.
More Cancer Drug Current Events and Cancer Drug News Articles
 | Physician's Cancer Chemotherapy Drug Manual 2008 (Jones and Bartlett Series in Oncology) by Edward Chu, Vincent T. DeVita Jr. Completely revised and updated for 2008, this practical handbook is an up-to-date guide to all aspects of cancer chemotherapy. The book provides a comprehensive, easy to use catalogue of over 100 drugs-both on- and off-label-commonly used in cancer treatment. A section on Common Chemotherapy Regimens provides a quick reference to management of specific cancers, arranged... |
 | Physicians' Cancer Chemotherapy Drug Manual 2003 (Physicians' Cancer Chemotherapy Drug Manual) by Edward Chu This pocket-sized volume will serve as both an in-depth reference as well as an immediate source of practical information that can be directly used by physicians and various health care professionals actively involved in the daily care of cancer... |
 | Cancer Drug Design and Discovery The ultimate source of information on the design of new anticancer agents, emphasising small molecules, this newest work covers recent notable successes resulting from the human genome and cancer genomics projects. These advances have provided information on targets involved in specific cancers that are leading to effective medicines for at least some of the common solid tumours. Unique sections... |
 | Tumor Models in Cancer Research (Cancer Drug Discovery and Development) (Cancer Drug Discovery and Development) Beverly A. Teicher and a panel of leading experts comprehensively describe for the first time in many years the state-of-the-art in animal tumor model research. The wide array of models detailed form the basis for the selection of compounds and treatments that go into clinical testing of patients, and include syngeneic models, human tumor xenograft models, orthotopic models, metastatic models,... |
 | Surviving Terminal Cancer: Clinical Trials, Drug Cocktails, and Other Treatments Your Oncologist Won't Tell You About by Ben A. Williams Describes how to use the Internet and other sources to learn about experimental drug trials, effective forms of alternative medicine, and other breakthroughs with the potential for dramatically improving the odds of successful... |
 | Platinum-Based Drugs in Cancer Therapy (Cancer Drug Discovery and Development) Leading international experts comprehensively review all aspects of platinum anticancer drugs and their current use in treatment, as well as examining their future therapeutic prospects. Writing from a variety of disciplines, these authorities discuss the chemistry of cisplatin in aqueous solution, the molecular interaction of platinum drugs with DNA, and such exciting new areas as DNA mismatch... |
 | Bioinformatics in Cancer and Cancer Therapy (Cancer Drug Discovery and Development) Bioinformatics can be loosely defined as the collection, classification, storage, and analysis of biochemical and biological information using computers and mathematical algorithms. Although no single person or group started the field wholly on their own, Temple Smith, Ph.D., a professor at Boston University, is generally credited with coining the term. Bioinformatics represents a marriage of... |
 | Antiangiogenic Agents in Cancer Therapy (Cancer Drug Discovery and Development) (Cancer Drug Discovery and Development) Antiangiogenesis remains a dynamic and evolving field in oncology. New therapeutic targets continue to emerge followed by the rapid development of new therapeutic agents to be investigated in clinical trials. Optimizing the therapeutic potential of antiangiogenic agents in combination with the other therapies in the armamentarium to fight cancer will be an on-going challenge. Antiangiogenic... |
 | American Cancer Society Consumer's Guide to Cancer Drugs, Second Edition (Jones and Bartlett Series in Oncology) by Gail Wilkes Current knowledge of the drugs used in cancer care is critical for today's practicing nurse. Drugs covered are described in terms of their mechanism of action, metabolism, drug interactions, laboratory effects/interference, and special considerations. Potential toxicities, side effects, and the nursing process are... |
 | In Vivo Imaging of Cancer Therapy (Cancer Drug Discovery and Development) Imaging studies are frequently used to evaluate the success of cancer treatments for a variety of tumor types. In Vivo Imaging of Cancer Therapy addresses a variety of cutting-edge imaging techniques, including their use for best practice, and provides examples of results found in both pre-clinical and clinical studies. This comprehensive text covers the entire spectrum of in vivo imaging for... |
| © 2008 BrightSurf.com |